Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients

NCT05535829 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05535829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients
Lead sponsor
RenJi Hospital
Phase
Observational
Overall status
Unknown status
Start date
August 1, 2022
Completion date
December 1, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarkers, fh-deficient rcc, systemic treatments